Abbott Laboratories (ABT) Q4 2021 earnings summary

Executive summary

• 2021 net sales reached $43.075B; organic sales grew 22.9% YoY excluding FX, with strength across all four major businesses. Adjusted ongoing EPS rose 42.7%.

• COVID-19 testing demand swung with vaccine rollout and Delta/Omicron waves, while underlying businesses also grew; monthly test production exceeded 150M units.

Financial highlights

• Net sales were $43.075B vs. $34.608B in 2020; GAAP sales increased 24.5% and organic sales increased 22.9% excluding FX.

• Operating earnings rose to $8.425B from $5.357B; net earnings were $7.071B vs. $4.495B, and diluted EPS from continuing operations was $3.94 vs. $2.49.

• Gross profit margin was 52.2% vs. 50.5%; operating margin was 19.6% vs. 15.5%. Higher volumes and utilization helped, partly offset by inflation, restructuring and unfavorable FX.

• Operating cash flow was $10.533B vs. $7.901B; capital expenditures were $1.885B vs. $2.177B.

Outlook and guidance

• 2022 priorities include meeting COVID-test demand, expanding Alinity adoption, growing Medical Devices and Nutritionals, and developing emerging-market pharmaceutical portfolios.

• R&D spending is targeted at ~7% of 2022 sales; planned work spans glucose monitoring, cardiac and vascular devices, diagnostics, and nutrition platforms.

• Inflation in raw materials, packaging and transportation is expected to continue in 2022, with at least partial mitigation from price increases and gross-margin initiatives.

• COVID-test demand is expected to remain volatile as the duration and severity of future variants are uncertain.